Jessica Baker FlechtnerBS, PhD
Dr. Flechtner joined Genocea in 2007, soon after the company was founded, and currently serves as Chief Scientific Officer. She is widely recognized as a pioneer in the development of novel vaccines directed toward T cell immunity and has more than 20 years of experience in immunology, cancer, infectious disease, and vaccine development. She leads Genocea’s efforts to develop T cell-directed vaccines and immunotherapies against cancer using the company’s proprietary ATLAS platform to identify and characterize both common and personalized antigens. Prior to joining Genocea, Dr. Flechtner served in a variety of roles developing vaccines and immunotherapies for cancer, infectious disease, autoimmunity, and allergy at companies including Mojave Therapeutics and Antigenics (now Agenus). She received a B.S. in Animal Science and a Ph.D. in Cellular Immunology from Cornell University, and performed her post-doctoral work at Dana Farber Cancer Institute and Harvard Medical School. Dr. Flechtner is a member of Women in Bio, the American Association of Immunologists, American Association for Cancer Research, Society for Immunotherapy of Cancer, President’s Council of Cornell Women, and American Society for Microbiology. She is also an inventor on numerous pending and issued patents and is the author of multiple peer-reviewed scientific publications.